Palivizumab for preventing severe respiratory syncytial virus (RSV) infection in children
CONCLUSIONS: The available evidence suggests that prophylaxis with palivizumab reduces hospitalisation due to RSV infection and results in little to no difference in mortality or adverse events. Moreover, palivizumab results in a slight reduction in hospitalisation due to respiratory-related illness and may result in a large reduction in RSV infections. Palivizumab also reduces the number of wheezing days. These results may be applicable to children with a high risk of RSV infection due to comorbidities. Further research is needed to establish the effect of palivizumab on children with other comorbidities known as risk factors for severe RSV disease (e.g. immune deficiencies) and other social determinants of the disease, including children living in low- and middle-income countries, tropical regions, children lacking breastfeeding, living in poverty, or members of families in overcrowded situations.PMID:34783356 | DOI:10.1002/14651858.CD013757.pub2
Source: Cochrane Database of Systematic Reviews - Category: General Medicine Authors: Luis Garegnani Lea Styrmisd óttir Pablo Roson Rodriguez Camila Micaela Escobar Liquitay Ignacio Esteban Juan Va Franco Source Type: research
More News: Breastfed | Bronchopulmonary Dysplasia | Cardiology | Children | Databases & Libraries | General Medicine | Heart | Heart Disease | Intensive Care | Respiratory Medicine | Study